IPP Bureau
Bayer and Aignostics to collaborate on next generation precision oncology
By IPP Bureau - March 16, 2024
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility
By IPP Bureau - March 16, 2024
The company is confident of addressing the concern raised by the USFDA
Indranil Sen, CFO, Biocon resigned
By IPP Bureau - March 16, 2024
Sen spent a decade with Biocon and held various key roles,
Abbott India appointed Swati Dalal as MD
By IPP Bureau - March 16, 2024
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Zydus launches generic version of Olaparib ‘IBYRA’ in India
By IPP Bureau - March 14, 2024
The drug will target specific genetic mutations prevalent in certain types of cancers
Cureskin secures US$ 20 million in Series B funding
By IPP Bureau - March 14, 2024
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
By IPP Bureau - March 14, 2024
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9
By IPP Bureau - March 14, 2024
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Nirma acquires majority stake in Glenmark Life Sciences
By IPP Bureau - March 13, 2024
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Jubilant Ingrevia partners with O2 Renewable to increase use of green energy
By IPP Bureau - March 13, 2024
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Evonik establishes a new research institute dedicated to skin sciences
By IPP Bureau - March 13, 2024
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Healthcare Triangle appoints Anand Kumar as Interim CEO
By IPP Bureau - March 13, 2024
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease
By IPP Bureau - March 13, 2024
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
